Innovations for next-generation antibody-drug conjugates
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
List view / Grid view
Dr Amrik Basran and Dr Matt Vincent discuss various developments for antibody-drug conjugates to treat cancer.
An engineered form of the SMOC1 protein has shown success as a type 2 diabetes treatment in animal models, say researchers.
Scientists have patented their technique of inhibiting cellular growth factor signalling to stop SARS-CoV-2 replication and treat COVID-19.
Researchers demonstrate that their novel small molecule, which activates the STING protein, supresses tumour growth and metastasis in a murine model of aggressive melanoma.
Researchers observed new structures of alpha-synuclein aggregates in their study exploring how the presence of cell membrane phospholipids impacts protein aggregation.
A study has shown that inhibiting sortilin, a neuroprotein known to have increased expression in cancers, reduces pancreatic cancer invasiveness in vitro.
Using cryogenic electron microscopy, scientists have observed the interaction between antibodies and their target molecules, providing information that could be utilised in the development of synthetic antibodies.
Researchers have found that the SARS-CoV-2 nucleocapsid protein may help the virus to spread from cell to cell, providing a drug target.
A protein called PPP1R1B has been revealed as a drug target for pancreatic cancer as it stopped the metastasis of tumours in mice.
A team has developed a predictive tool called TransComp-R which could be used to reveal whether new drugs that have been effective in animals will have positive outcomes in humans.
Researchers have shown that using antisense oligonucleotides to reduce the levels of prion protein in lab animals with prion disease can extended their survival.
The SARS-CoV-2 Spike protein from a COVID-19 vaccine candidate has been characterised by researchers, supporting the neutralising antibody response it elicits.
A flow mode Raman-activated cell sorter called FlowRACS has been created by researchers for high-throughput discovery of enzymes and their cell factories.
A phenotypic chemical screen has been developed that could be used to discover molecular glue degraders which induce the degradation of target proteins.
According to researchers, drugs that target envelope protein E on the SARS viral membrane could also be used to target a similar protein on COVID-19.